However, in this trial, the survival benefit occurred regardless of PD‐L1 expression on the tumor with several cut‐off values of 1, 5, and 10, although patients with PD‐L1 ≥ 1%, tumor cells had a 15% greater reduction in the risk of death than those with PD‐L1 < 1%. This evidence concerns the gene CD274 and neoplasm.